옵션 체인은 다양한 행사가격과 만기일에 대한 SCYNEXIS의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 SCYNEXIS에 대한 시장 심리를 평가합니다..

SCYNEXIS (NASDAQ:SCYX) 주식, 옵션 체인

SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

SCYNEXIS Inc

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025.
SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global 2025 continue to build upon SCY-247's positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections, including its potent antifungal activity against multi drug-resistant fungi.

Biotech

News

General

SCYX

SCYNEXIS To Present Preclinical Data On Second Generation IV/Oral Fungerp SCY-247 At The European Society Of Clinical Microbiology And Infectious Diseases

Earnings

SCYNEXIS 2024 GAAP EPS $(0.44) Down From $1.39 YoY, Sales $3.75M Down From $140.14M YoY

SCYNEXIS Initiates Dosing In Phase 1 TrialOof SCY-247 For Invasive Fungal Infections

SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 50 percent decrease over losses of $(0.04) per share from the same period last year.

Earnings Beats

SCYNEXIS Q3 EPS $(0.06) Beats $(0.07) Estimate

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024. &nbsp;
Presentation details can be found below:
Oral Presentation:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections</td>
</tr>
<tr>
<td>Session:</td>
<td>Mycology Matters: Insights into Fungal Infections</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>Thursday October 17, 2024 at 10:45 AM PDT</td>
</tr>
<tr>
<td>Location:</td>
<td>Los Angeles Convention Center, Room 403 B</td>
</tr>
<tr>
<td>Presenting author:</td>
<td>David A. Angulo, M.D., President and CEO of SCYNEXIS</td>
</tr>
</tbody>
</table>
</figure>
 Poster Presentation:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td>SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential</td>
</tr>
<tr>
<td>Session:</td>
<td>New Drug Development</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>Friday October 18, 2024 at 12:15 – 1:30 PM PDT</td>
</tr>
<tr>
<td>Location:</td>
<td>Los Angeles Convention Center, Halls JK</td>
</tr>
<tr>
<td>Presenting author:</td>
<td>David A. Angulo, M.D., President and CEO of SCYNEXIS</td>
</tr>
</tbody>
</table>
</figure>
 For more information, see the IDWeek website <a href="https://www.globenewswire.com/Tracker?data=6hJ60YVzqYkIPXldH-wotp4NTWYc83wNsK-9McWX8cfhFSI8ij-8-icJ86IP903N">here</a>.

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At IDWeek 2024

SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 105 percent. The company reported quarterly sales of $1.400 million which beat the analyst consensus estimate of $303.000 thousand by 362.05 percent. This is a 23.89 percent increase over sales of $1.130 million the same period last year.

SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate

<ul>
<li>In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata &nbsp;</li>
<li>SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species &nbsp;</li>
</ul>
JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 at the ESCMID Global 2024 congress (formerly known as ECCMID) in Barcelona, Spain from April 27-30, 2024.
"We continue to be excited about the potential of our second generation fungerp SCY-247 to address the critical need for new antifungal treatments, particularly for invasive fungal infections where current options are limited and resistance is increasing," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. "The positive data presented at ESCMID Global further strengthen our confidence in SCY-247's ability to combat these difficult-to-treat infections, and we look forward to its continued advancement as we aim to enter clinical stage by year end."
Nathan Wiederhold, Pharm.D., Professor, Director – Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio, delivered an oral presentation entitled, "The novel second-generation IV/oral triterpenoid SCY-247 is efficacious in an experimental murine model of invasive candidiasis caused by Candida glabrata." C. glabrata, a high priority fungal pathogen on the World Health Organization fungal priority pathogens list (WHO FPPL), is a major cause of invasive candidiasis with an increasing rate of resistance against current antifungals. In a mouse model of invasive candidiasis caused by C. glabrata, SCY-247 showed promising in vivo efficacy. Following inoculation with C. glabrata, mice were treated with either vehicle control, oral SCY-247 (16, 32, &amp; 48 mg/kg), oral fluconazole 20 mg/kg, or parenteral caspofungin 1 mg/kg for 7 days. In mice treated with SCY-247, dose-dependent reductions of fungal burden in both kidneys and lungs were observed. Fungal burden within the kidneys was significantly lower in each SCY-247 group versus vehicle (p0.01 for all comparisons). Lung fungal burden in the SCY-247 32 mg/kg and 48 mg/kg groups was also significantly lower versus placebo (p0.01 for both comparisons). In contrast, caspofungin significantly lowered fungal burden within the kidneys (p=0.01) but not the lungs, while fungal burden in mice treated with fluconazole was similar to controls in both organs. The findings in this model illustrate the meaningful efficacy of SCY-247 against C. glabrata, its ability to reach efficacious concentrations after oral administration and suggests an improved lung penetration of SCY-247 relative to echinocandins.
Dr. Wiederhold also presented a poster entitled, "SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus." In this study, SCY-247 was tested against 155 clinical isolates of yeasts, molds and dimorphic fungi. SCY-247 demonstrated in vitro activity against a broad range of pathogenic fungi, with the most potent activity observed against Candida species including C. albicans, C. auris, and C. glabrata as well as fluconazole-resistant strains. Potent activity was also observed against Aspergillus species, including voriconazole-resistant isolates, and against the dimorphic fungi Blastomyces dermatitidis, Histoplasma capsulatum, and Coccidioides species.
Both studies presented by Dr. Wiederhold have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract nos. HHSN272201700039 and 75N93019D00022.
A second poster entitled, "Effect of SCY-247, a second-generation triterpenoid antifungal, on growth kinetics and ultrastructure of Candida auris," was presented by Mahmoud Ghannoum, Ph.D., Professor, Case Western Reserve and Director, Center for Medical Mycology, University Hospitals Cleveland Medical Center. In this study, the antifungal effect of SCY-247 on cell morphology of both susceptible and multi-drug resistant C. auris was evaluated using Scanning Electron Microscopy (SEM) imaging. Results demonstrated that SCY-247 significantly inhibited the growth of both C. auris strains. Importantly, SCY-247 had a prominent effect on fungal cell morphology and significantly reduced fungal growth.
About Invasive Fungal Infections
Candida auris, a critical priority fungal pathogen in WHO fungal priority pathogens list (WHO FPPL), is an emerging fungal pathogen associated with nosocomial infections and considered a serious global health threat. It is often resistant to commonly used antifungal drugs, with about 90% of U.S.&nbsp;C. auris&nbsp;samples resistant to fluconazole and some&nbsp;C. auris&nbsp;strains resistant to all three main classes of antifungals (azoles, echinocandins and polyenes). Candida glabrata is the most common non-albicans species causing systemic fungal infections. It also has high levels of resistance to fluconazole, and echinocandin resistance appears to be increasing. Patients withCandida&nbsp;infections that are resistant to both fluconazole and echinocandin drugs have very few treatment options.&nbsp;Azole-resistant&nbsp;Aspergillus infections are also difficult to treat, and affected patients are up to 33% more likely to die than patients with infections that can be treated with azoles.
About SCY-247
SCY-247 is a second-generation antifungal compound, from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), being developed to address systemic fungal diseases. The triterpenoid class of antifungals represents the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. SCY-247 is in pre-IND development stage and has demonstrated in vitro and in vivo broad-spectrum antifungal activity, including in MDR isolates (or spp.). SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247.

SCYNEXIS Presented Preclinical Data On Second Generation Fungerp SCY-247 At The Congress Of The European Society Of Clinical Microbiology And Infectious Diseases

Cantor Fitzgerald analyst Louise Chen reiterates SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on SCYNEXIS

SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.20) by 95 percent. This is a 30 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $5.80 million which beat the analyst consensus estimate of $1.37 million by 323.14 percent. This is a 314.07 percent increase over sales of $1.40 million the same period last year.

Earnings Misses

SCYNEXIS Q4 EPS $(0.39) Misses $(0.20) Estimate, Sales $5.80M Beat $1.37M Estimate

<ul>
<li>In vivo&nbsp;data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis &nbsp;</li>
<li>Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies</li>
</ul>
&nbsp;

SCYNEXIS Presented Preclinical Data On Second Generation Fungerp SCY-247 Against Mucormycosis At 11th Advances Against Aspergillosis and Mucormycosis Conference

<h3>What is a Value Stock?</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) - P/E: 0.07</li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) - P/E: 2.62</li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) - P/E: 1.26</li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) - P/E: 8.08</li>
<li>Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) - P/E: 7.34</li>
</ol>
CalciMedica's earnings per share for Q3 sits at $-0.82, whereas in Q2, they were at -1.11. Quoin Pharmaceuticals's earnings per share for Q3 sits at $-1.95, whereas in Q2, they were at -2.13. This quarter, SCYNEXIS experienced a decrease in earnings per share, which was $2.46 in Q2 and is now $-0.04. Syros Pharmaceuticals has reported Q3 earnings per share at $-1.43, which has decreased by 10.0% compared to Q2, which was -1.3. Most recently, Organon reported earnings per share at $0.87, whereas in Q2 earnings per share sat at $1.31. Most recently, the company reported a dividend yield of 7.65%, which has increased by 2.51% from last quarter's yield of 5.14%.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

CALC

QNRX

SYRS

5 Value Stocks To Watch In The Healthcare Sector

<h3>What is a Value Stock?</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:</h2>
<ol>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) - P/E: 0.33</li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) - P/E: 7.63</li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) - P/E: 0.96</li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) - P/E: 1.27</li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) - P/E: 1.85</li>
</ol>
Exicure saw an increase in earnings per share from -0.7 in Q1 to $-0.68 now. Voyager Therapeutics saw a decrease in earnings per share from -0.51 in Q2 to $-0.59 now. MEI Pharma's earnings per share for Q1 sits at $8.46, whereas in Q4, they were at -1.51. Most recently, SCYNEXIS reported earnings per share at $-0.04, whereas in Q2 earnings per share sat at $2.46. Most recently, Community Health Sys reported earnings per share at $-0.33, whereas in Q2 earnings per share sat at $-0.22. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

MEIP

VYGR

XCUR

A Look Into Healthcare Sector Value Stocks

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024. &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">Poster Presentation:</td>
</tr>
<tr>
<td>Title:</td>
<td>SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Presenting author:</td>
<td>Dr. Ashraf Ibrahim, PhD, FAAM, FECCM (Professor of Medicine, Division of Infectious Disease, David Geffen School of Medicine UCLA)</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
In this preclinical study, SCY-247 demonstrated in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice. Notably, the combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy. &nbsp;
"The results from this preclinical study are very encouraging and illustrate the significant potential for this novel fungerp candidate SCY-247," said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. "Groundbreaking treatment options are urgently needed to address the significant limitations in effective therapies for devastating and very often lethal fungal diseases such as mucormycosis. We continue to expeditiously progress the development of this promising antifungal with plans to begin a clinical study by year end."
For more information, see the AAAM website <a href="https://www.globenewswire.com/Tracker?data=giSEYPCM8GJWE9QLiiAdhVUUoN4gnj0Rzq6GwpbbW_qc1Eyr7G22z4hF1ko1hnat6cSo8cYXGcpfnbyXY5q-Vg==">here</a>.
The study was funded by the National Institutes of Health (NIH) under NIH Task order A65 75N93022F00001 utilizing the National Institute of Allergy and Infectious Diseases (NIAID) suite of preclinical services for&nbsp;in vivo&nbsp;testing.
About SCY-247
SCY-247 is a second generation antifungal compound, from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), under development as therapeutic options for systemic fungal diseases. The triterpenoid class of antifungals represents the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. SCY-247 is in pre-IND development stage and has demonstrated broad-spectrum antifungal activity, in vitro and in vivo. SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247.

Events

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Advances Against Aspergillosis And Mucormycosis Conference, January 25 – 27, in Milan, Italy

Shares of Resources Connection, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgp#NASDAQ">RGP</a>) rose sharply in pre-market trading following better-than-expected results for its second quarter.
Resources Connection posted quarterly adjusted earnings of 28 cents per share, beating market estimates of 18 cents per share. The company&rsquo;s quarterly sales came in at $163.1 million versus expectations of $161.936 million.
Resources Connection shares jumped 6.5% to $14.58 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Jeffs&#39; Brands Ltd(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) gained 60.6% to $5.06 in pre-market trading after surging 25% on Wednesday. Jeffs&#39; Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) rose 41% to $0.1984 in pre-market trading after falling over 11% on Wednesday. Kintara Therapeutics, last month, announced a review of strategic alternatives focused on maximizing stockholder value.</li>
<li>The Arena Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aren#NYSE">AREN</a>) shares rose 26.8% to $2.65 in pre-market trading after falling over 9% on Wednesday. Arena Group Board, last month, terminated employment of CEO Ross Levinsohn.</li>
<li>180 Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnf#NASDAQ">ATNF</a>) shares gained 24.4% to $0.2550 in pre-market trading. 180 Life Sciences, last month, engaged financial advisor to explore strategic alternatives.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) shares climbed 10.2% to $0.2259 in pre-market trading after falling over 6% on Wednesday. Advent Technologies recently announced a $2 million registered direct offering of common stock.</li>
<li>BRF S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brfs#NYSE">BRFS</a>) shares rose 9.8% to $2.80 in pre-market trading. JP Morgan analyst Lucas Ferreira, last month, downgraded BRF from Overweight to Neutral.</li>
<li>Affimed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afmd#NASDAQ">AFMD</a>) shares gained 9.3% to $0.6426 in pre-market trading after declining 6% on Wednesday. Affimed announced sale of wholly-owned subsidiary AbCheck for $6 million.</li>
<li>SCYNEXIS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/scyx#NASDAQ">SCYX</a>) gained 8.7% to $2.13 in pre-market trading after falling 11% on Wednesday.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) gained 8.4% to $4.01 in pre-market trading after falling 8% on Wednesday. Brooge Energy recently reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>SELLAS Life Sciences Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sls#NASDAQ">SLS</a>) shares fell 26.3% to $0.6674 in pre-market trading after announcing a proposed public offering.</li>
<li>Hallmark Financial Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hall#NASDAQ">HALL</a>) shares fell 20.5% to $0.74 in pre-market trading after declining around 25% on Wednesday. Hallmark Financial Services, on Dec. 26, announced that it intends to voluntary delist from the Nasdaq.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) shares fell 15.3% to $4.62 in pre-market trading. First Wave BioPharma shares jumped 43% on Wednesday after Roth MKM maintained a Buy rating on the stock and adjusted its target from $11 to $40.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) shares fell 15.1% to $1.64 in pre-market trading. ABVC BioPharma shares jumped over 60% on Wednesday after the company and its subsidiary received a milestone payment of 46 million shares from AiBtl BioPharma under a global licensing payment.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) shares fell 14.8% to $1.26 in pre-market trading after dipping 61% on Wednesday.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares fell 13.8% to $1.56 in pre-market trading after surging over 86% on Wednesday.</li>
<li>Evotec SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evo#NASDAQ">EVO</a>) shares fell 11.4% to $9.37 in pre-market trading. Evotec and Owkin announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares fell 10.4% to $0.2631 in pre-market trading after dipping around 35% on Wednesday.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) fell 8.9% to $5.65 in pre-market trading after jumping around 153% on Wednesday.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) fell 5.3% to $51.94 in pre-market trading after the company reported downbeat results for its second quarter.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36484761/walgreens-conagra-brands-and-3-stocks-to-watch-heading-into-thursday"> Walgreens, Conagra Brands And 3 Stocks To Watch Heading Into Thursday</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABVC

AFMD

AREN

ATNF

BRFS

BROG

CALM

FWBI

HALL

JFBR

Kintara Therapeutics, Inc. - Common Stock

KTRA

NEXI

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) stock increased by 84.4% to $4.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) shares moved upwards by 75.0% to $2.1. The company's market cap stands at $16.2 million. </li>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) shares increased by 46.07% to $5.58. The market value of their outstanding shares is at $3.7 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock rose 45.4% to $18.99. The company's market cap stands at $1.1 billion. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) shares increased by 19.04% to $1.25. The company's market cap stands at $98.3 million. </li>
<li>Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) shares moved upwards by 18.26% to $27.0. The market value of their outstanding shares is at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nemaura Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRD#NASDAQ">NMRD</a>) shares declined by 20.8% to $0.15 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) stock declined by 18.5% to $2.38. The market value of their outstanding shares is at $270.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 9.65% to $1.3. The market value of their outstanding shares is at $46.1 million. </li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) stock decreased by 8.6% to $2.02. The market value of their outstanding shares is at $75.1 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock declined by 8.13% to $1.47. The market value of their outstanding shares is at $1.1 million. </li>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) stock declined by 7.8% to $0.46. The market value of their outstanding shares is at $39.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGIO

CLDI

ESPR

NMRD

NRXP

SNES

VNRX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>First Wave BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWBI#NASDAQ">FWBI</a>) shares increased by 40.8% to $5.38 during Tuesday's after-market session. The company's market cap stands at $3.6 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock rose 7.72% to $4.46. The company's market cap stands at $2.3 million. </li>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock moved upwards by 6.48% to $1.15. The market value of their outstanding shares is at $3.9 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 6.4% to $0.68. The market value of their outstanding shares is at $24.3 million. </li>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) shares increased by 5.97% to $1.95. The market value of their outstanding shares is at $4.8 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock moved upwards by 5.24% to $3.15. The market value of their outstanding shares is at $19.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 12.6% to $0.47 during Tuesday's after-market session. The company's market cap stands at $16.4 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock fell 6.42% to $0.6. The company's market cap stands at $7.2 million. </li>
<li>Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) shares decreased by 5.72% to $0.62. The market value of their outstanding shares is at $159.0 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares declined by 5.67% to $1.5. The company's market cap stands at $12.6 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares decreased by 4.99% to $0.19. The market value of their outstanding shares is at $4.2 million. </li>
<li>SCYNEXIS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>) stock decreased by 4.98% to $2.1. The market value of their outstanding shares is at $78.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRX

BBLG

BFRG

BIOL

NDRA

OCGN

ONCO

SIEN

SSKN

12 Health Care Stocks Moving In Tuesday's After-Market Session

-SEC Filing&nbsp;Granted for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). The terms of the License Agreement are further
-SEC Filing
&nbsp;
Granted for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). The terms of the License Agreement are further described in SCYNEXIS's Form 8-K dated March 30, 2023.

Contracts

SCYNEXIS Entered Into Binding MoU For Amendment To License Agreement Between Co And GSK; Granted GSK Royalty-Bearing, License For Development, Manufacture, And Commercialization Of Ibrexafungerp, Including The Approved Product BREXAFEMME

SCYNEXIS Q3 EPS $(0.04) Vs $(0.62) Last Year, Sales $1.76M vs $1.56M Last Year

The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve University, in an oral presentation titled, "SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against a Broad-spectrum of Fungal Pathogens, and Dose-dependent Tissue Distribution In Vivo" at the 11th Congress on Trends in Medical Mycology (TIMM) held in Athens Greece October 20-23, 2023. &nbsp;

SCYNEXIS Presents New Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) being held in Athens Greece, October 20-23, 2023. &nbsp;
Oral Presentation:
Title: SCY-247, a Second-generation IV/Oral Triterpenoid Antifungal: In Vitro Activity Against Broad-spectrum of Fungal Pathogens, and Dose-Dependent Tissue Distribution In Vivo
Session: Symposium 8: Clinic meets Pharmacology: Antifungal treatment Abstract number: S08.6 Date: Saturday, October 21 Time: 3:35 p.m EEST / 8:35 a.m. EDT Presenting author: Mahmoud Ghannoum, Ph.D. (Ohio, United States)
Location: Room MC3, Megaron Athens International Conference Center
For more information, see the TIMM website <a href="https://www.globenewswire.com/Tracker?data=5RDArZCeNFvcMqApI50IRgoakSWFpic9ygk5XhS1eb_LswY5gNe6L7EZEzpQ-_YN6QxONpdl9my5IOXXSsC7_g==">here</a>.
About SCY-247
SCY-247 is a second-generation antifungal compound from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), under development as a therapeutic option for systemic fungal diseases. The fungerps represent the first new class of antifungal compounds since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility for oral and intravenous (IV) routes of administration. SCY-247 has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, and SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for its IV and oral formulations. SCYNEXIS plans to begin clinical studies in the second half of 2024.

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology October 20-23 In Athens, Greece

Financing

Press Releases

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Health Care

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Comments

SCYNEXIS

SCYNEXIS (SCYX) 옵션

SCYNEXIS (NASDAQ:SCYX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌